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ABSTRACT 
The purpose of the study was to analyze the relationship between treatment adherence, quality of life and clinical vari- 
ables in HIV/AIDS Infection. The empirical study was conducted at two Portuguese hospitals (Porto and Lisbon) with a 
sample of 295 outpatients diagnosed with HIV/AIDS attending the Infectology service and on antiretroviral medication, 
during a 12-month period (February 2009 to February 2010). Data were collected by voluntary fulfillment of three 
questionnaires: one for socio-demographic variables, one to Assess Adherence to Antiretroviral Treatment-HIV and the 
Portuguese version of the WHOQOL-Bref to measure the quality of life (QoL). Clinical records were inspected in order 
to collect clinical information from the patients. The relationship between these variables was accessed by Student’s 
t-test and ANOVA using Tukey and LSD as the post Hoc test. Regarding disease stages, the post Hoc analysis has 
showed that asymptomatic patients have a better level of adherence and quality of life when compared to those in more 
advanced stages of the disease. Undetectable viral load <20 copies/mL and T CD4+ count >500 cells/mm3 were also 
associated with higher QoL in all overall domains. Patients on NRTI + NNTRI regimens have higher adherence when 
compared to those on NRTI + PI regimens and higher QoL indexes when compared to twice daily regimens, patients on 
single dose per day regimens have higher adherence and higher QoL in overall domain. Patients experiencing adverse 
effects have lower QoL and lower adherence levels when compared to those not experiencing such events. We consider 
the multiplicity and the interaction of several determinants of influence in the adaptation process during the HIV/AIDS 
treatment. The results may have implications for the psychological intervention to improve the adherence’s level to the 
antiretroviral therapy. 
 
Keywords: Adherence; Quality of Life; HIV/AIDS 
1. Introduction 
The introduction of Highly Antiretroviral Therapy (HAART) 
has had a major impact on both life expectancy and qual- 
ity of life of HIV-infected individuals [1-3]. Although 
clearly providing significant benefits, combination ther- 
apy is often associated with complicated regimens and 
non-negligible side effects. The new generation of HIV 
drugs offers the potential for long-term suppression of 
HIV replication, however the challenge is to encourage 
and enable patients to take these medications correctly, in 
order to achieve their maximum effect. Some studies have 
found that adherence lower than 95% can be associated 
with the development of viral resistance to medication 
[4-7]. HAART regimes are composed of several drugs 
and distinct intake requirements (namely, with or without 
food, once or twice daily, the need for special storage con- 
ditions) for each drug within the regime, resulting in com- 
plex regimens. Many patients report difficulties to meet 
the requirements due to the complexity of treatment, re- 
quiring intervention and psychological support to over- 
come or improve the level of adherence to HAART [8]. 
If gaps in dose intake or other forms of inadequate ad- 
herence occur, the virus acquires the ability to replicate 
thereby increasing the risk of viral resistance [9]. The evi- 
dence on the association between clinical variables and 
HAART adherence is abundant [6,9-14] and indicates 
that adherence is associated with lower viral load, higher 
counts of lymphocytes T CD4+, asymptomatic stage, and 
less experience of adverse events of antiretroviral medi- 
cation [12,13,15]. 
*The authors declare no conflict of interest in publishing this article. 
#(PhD Grant—Scholarship for Doctor’s Degree from the Science and 
Technology Foundation—SFRH/BD/43241/2008). 
Copyright © 2013 SciRes.                                                                                 WJA 
Treatment Adherence, Quality of Life and Clinical Variables in HIV/AIDS Infection 240 
Considering the relevance of the topic, this work, 
which is part of a broader study [13] aims at analyzing 
the relationship between treatment adherence, quality of 
life, and HIV/AIDS infection surrogate markers.  
2. Method 
2.1. Ethics Statement 
The study received favorable ethical statement from the 
Portuguese Data Protection (CNPD) as well as by the 
Joaquim Urbano’s hospital (Porto, Portugal) and Curry 
Cabral’s hospital (Lisboa, Portugal) ethical committees. 
The participation was voluntary and the informed con- 
sent was signed by all participants. 
2.2. Data Collection 
The data was collected between February of 2009 and 
February of 2010, in two major infectious disease centers 
in Portugal (Joaquim Urbano Hospital in Porto and Curry 
Cabral Hospital in Lisbon).  
Patients on the same antiretroviral regimen for at least 
3 months were invited, by the infectious disease special- 
ist, to participate in the study. 
The research protocol was completed, in the presence 
of a psychologist, at the end of the physician appoint- 
ment. This research protocol consisted of patients’ clini- 
cal records inspection in order to collect participants’ cli- 
nical information and the fulfillment of three question- 
naires: one for socio-demographic variables, one to As-
sess Adherence to Antiretroviral Treatment-HIV (Por- 
tuguese adaptation of the CEAT-VIH) [6,16] and one to 
measure the quality of life (QoL) (Portuguese version of 
the WHOQOL-Bref) [17]. 
2.3. Instruments 
2.3.1. Questionnaire Sample Characterization 
This questionnaire includes information on both socio- 
demographic variables (sex, age, civil status, occupation, 
schooling) and clinical (mode of transmission, time since 
infection, HIV stage [18], viral load, lymphocyte T CD4+ 
count, presence of adverse events of antiretroviral treat- 
ment and current antiretroviral regimen. 
2.3.2. Questionnaire for Assessing Adherence to  
Antiretroviral Treatment (CEAT-VIH,  
in the Original) 
The CEAT-VIH is a 20 items multidimensional instru- 
ment, of self-administration, validated for antiretroviral 
regimen adherence assessment in HIV infected adult in- 
dividuals. This quick and simple tool addresses the main 
factors associated to adherence behaviors. The question- 
naire score varies between 19 and 81 and a higher score 
indicates a higher level of adherence to treatment [6,19]. 
The CEAT-VIH was originally developed in Spain [6] 
and later adapted to Brazil [7] Colombia [20], Mexico 
[21], Peru [22] and Roménia [23]. In the present study 
[12,16] the CEAT-VIH was adapted to Portugal’s Portu- 
guese and the internal consistency was assessed through 
the Cronbach’s alpha (0.89 for the present study). 
2.3.3. World Health Organization Quality of Life— 
WHOQOL-Bref  
The WHOQOL-Bref, short version of WHOQOL-100, is 
a tool of quality of life assessment organized in four do- 
mains and a general feature (two items) regarding the as- 
sessing of global quality of life [17]. The internal consis- 
tency for each domain was assessed through the Cron- 
bach’s alpha and it was the following: physical health 
(0.78), psychological (0.79), social relationships (0.79) 
and environment (0.83). The questionnaire score varies 
between 0 and 100 with a higher score representing bet- 
ter quality of life.  
2.4. Participants 
The sample was collected randomly in reference centers 
mentioned above and it’s a non-representative sample. 
As presented in Table 1, the sample consists of 295 
participants diagnosed with HIV/AIDS Infection both 
female (n = 105; 35.6%) and male (n = 190; 64.4%) and 
aged between 19 and 81 years [Mean (M) = 40.9 years, 
Standard Deviation (SD) = 9.5]. Regarding marital status, 
47.5% are single, 36.6% are married and/or cohabitate) 
and 12.9% are separated and/or divorced. Regarding edu- 
cation, participants is distributed as follows: Basic Edu- 
cation†: 1st cycle (n = 75; 25.4%), 2nd cycle (n = 70; 
23.7%), 3rd cycle (n = 72; 24.4%); Secondary education 
(n = 37; 12.5%) and Tertiary education (n = 26; 8.8%). In 
what concerns occupation, 33.6% (n = 99) of the partici- 
pants are professionally active, 39.3% (n = 116) unem- 
ployed and 17.3% are retired (n = 51). The remaining 
percentage correspond to domestic workers, people who 
have never worked or are currently on sick leave (n = 29; 
9.8%). 
According to the data presented in Table 1 the most 
frequent transmission mode was heterosexual sex (n = 
159; 52.9%). At the time of interview, 56.9% participants 
were in stage A1 (asymptomatic) of HIV infection [13] 
and the average time of infection was 103.4 months (SD 
= 60.2). Of the total number of participants included in 
the sample, regarding clinical indicators of HIV/AIDS 
infection, 34.6% have undetectable viral load (<20 cop- 
ies/ml). Considering participants who are not with unde- 
tectable viral load it was found that only 5.08% had val- 
es above 100,000 copies. The average lymphocyte T  u   
†In Portugal, Basic Education consists of nine years of schooling di-
vided into three sequential cycles of education of four, two and three 
years.
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Table 1. Clinical data (n = 295). 
Clinical data Subcategories n % Min Max M SD 
Mode of transmission   
 Heterosexual 156 52.9     
 Homosexual 36 12.2     
 IVDU 99 33.6     
Disease stage CDC (Centre for Disease Control)   
 Asymptomatic 168 56.9     
 Symptomatic 49      
 AIDS 78      
Time since infection (in months)    4 252 103.4 60.2 
Viral load (HIV RNA cps/mL)    <20 750,000 20688.3 91614.6
 <20 102 34.6     
 20 - 50 128 43.4     
 51 - 500 20 6.8     
 501 - 10,000 14 4.7     
 10,001 - 30,000 1 0.3     
 >100,000 15 5.08     
        
CD4+ count    8 1556 454.4 308.4 
 <200 65 22.0     
 200 - 350 63 21.4     
 351 - 500 65 22.0     
 >500 102 34.6     
Third agent Drug Class        
 NRTI* + NNRTI** 194 66.4     
 NRTI + PI*** 98 33.6     
Number of doses/day    1 3 1.5 0.5 
 1 158 53.6     
 2 134 45.4     
 3 3 1.0     
Number of pills/day    1 9 3.7 1.8 
 1 26 8.8     
 2 53 18.0     
 3 90 30.5     
 4 37 12.5     
 >4 89 30.2     
Adverse events of antiretroviral medication        
 yes 113      
 No 182      
*Nucleoside reverse transcriptase inhibitors; **Non nucleoside reverse transcriptase inhibitors; ***Protease inhibitors. 
Treatment Adherence, Quality of Life and Clinical Variables in HIV/AIDS Infection 242 
 
CD4+ count was 455.8 (SD = 308.4), ranging between 
and 1556. Of the total participants, 22% presented lym- 
phocyte T CD4+ count <200. The most common antiret- 
roviral regimen is a combination of two Nucleoside Re- 
verse Transcriptase Inhibitors (NRTI) with one Non-nu- 
cleoside Reverse Transcriptase Inhibitors (NNRTI) (53.9%). 
The simplest regimen provides one pill per day and 8.8% 
of the participants are under that regimen. 53.6% of the 
participants are on a daily regimen and the average num- 
ber of pills per day is 3. 7 (SD = 1.8). Finally, 38.3% of 




For data analysis it was used the informatics program 
SPSS (Statistical Package for Social Sciences—version 
17) to treat the data statistically. At first the data analysis 
included a description of the variables in study. Then, for 
the study of adherence and quality of life differences and 
considering the clinical variables, it was used the para- 
metric statistics after the normality of the sample was 
tested and assumed (t tests of Student and ANOVA ana- 
lysis with post-hoc Tukey and LSD). 
3. Results 
Tables 2 to 10 present the estimated association between 
the variables under analysis (adherence and quality of life) 
and the presumed relevant factors (clinical variables). 
Overall, results suggest a statistically significant associa- 
tion between clinical variables considered (viral load, 
lymphocyte T CD4+ count, antiretroviral regimen, and 
number of intakes per day, number of pills per day and 
adverse events of antiretroviral medication at the time of  
the data collection) and adherence and quality of life. 
As shown in Table 2, it can be seen that there are sig- 
nificant differences in adherence and in all domains of 
quality of life, including the general facet, depending on 
the CDC HIV stage [13]. In addition, Tukey’s tests were 
calculated to detect the direction of these differences 
having been found that infected individuals in an asymp- 
tomatic stage have better compliance and higher scores 
in all domains of quality of life. There were no statistical- 
ly significant differences between the symptomatic pa- 
tients and those undergoing AIDS (Table 3).  
With regard to viral load, it can be verified by reading 
Table 4 that adherence and quality of life are higher in 
participants with undetectable viral load, except for the 
field of social relations in which no statistically signifi- 
cant differences were found. With respect to CD4+ T cell 
count, statistically significant differences in adherence 
and in all domains of quality of life, except for the psy- 
chological domain (Table 5), were obtained. Through the 
Tukey’s test (p < 0.001) it was found that participants 
with CD4+ > 500/mm3 have higher adherence and better 
quality of life (Table 6).  
In terms of the therapeutic regimen, Table 7 shows 
that participants with NRTI + NNRTI prescription pre- 
sent higher compliance and better quality of life, in the 
physical, environment and general facet. Table 7 also in- 
dicates that participants who reported experiencing side 
effects of antiretroviral therapy have lower levels of ad- 
herence and worse quality of life. 
With regard to the number of intakes per day, there are 
statistically significant differences in adherence and qua- 
lity of life for participants in a single dose regimen, 
except for the domain of social relationships (Table 8).  
Concerning the number of tablets per day there are 
statistically significant differences in adherence and in  
 
Table 2. Mean differences (One-Way ANOVA) in treatment adherence and quality of life according to HIV stage (CDC). 
HIV stage (CDC) 
Asymptomatic Symptomatic AIDS 
 
(n = 168) (n = 49) (n = 78) 
 
 M SD M SD M SD F p 
Adherence 74.18 8.62 65.57 10.72 68.72 12.34 17.29 <0.001 
General QoL* 57.07 20.46 50.77 22.45 45.83 20.11 8.19 <0.001 
QoL domains         
Physical health 63.88 18.40 54.45 16.01 54.62 15.13 10.62 <0.001 
Psychological 61.01 17.14 53.49 16.95 53.47 18.66 6.68 0.001 
Social relationships 55.51 22.22 48.98 20.03 45.19 20.12 6.70 0.001 
Environment 56.62 16.27 51.72 16.29 49.80 18.20 4.93 0.008 
*Quality of life. 
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Table 3. Mean differences (One-Way ANOVA) in treatment adherence and quality of life according to HIV stage (CDC)— 
Post-hoc Tukey. 
 HIV stage (CDC) HIV stage (CDC) Mean difference p 
Symptomatic 8.61 <0.001 
Asymptomatic 
AIDS 5.46 <0.001 Adherence 
Symptomatic AIDS −3.15 0.203 
Symptomatic 6.30 0.15 
Asymptomatic 
AIDS 11.24 <0.001 General QoL* 
Symptomatic AIDS 4.93 0.39 
QoL domains:     
Symptomatic 9.34 0.002 
Asymptomatic 
AIDS 9.26 <0.001 Physical health 
Symptomatic AIDS −0.18 0.99 
Symptomatic 7.53 0.02 
Asymptomatic 
AIDS 7.54 0.005 Psychological 
Symptomatic AIDS 0.014 1.00 
Symptomatic 6.26 0.15 
Asymptomatic 
AIDS 10.31 0.001 Social relationships 
Symptomatic AIDS 3.79 0.59 
Symptomatic 4.90 0.17 
Asymptomatic 
AIDS 6.82 0.009 Environment 
Symptomatic AIDS 1.92 0.81 
*Quality of life. 
 
Table 4. Mean differences (One-Way ANOVA) in treatment adherence and quality of life according to the viral load. 
  Viral load 
  <20 >20  
  (n = 102) (n = 193)  
  M SD M SD t p 
Adherence  77.43 5.20 68.07 11.33 9.71 <0.001 
General QoL*  56.37 18.08 51.30 22.53 2.10 0.04 
QoL domains:        
Physical health  66.60 17.65 56.31 16.81 4.91 <0.001 
Psychological  63.97 16.03 54.49 17.95 4.47 <0.001 
Social relationships  53.76 21.83 50.60 21.68 1.19 0.24 
Environment  57.02 14.46 52.41 18.07 2.38 0.02 
*Quality of life. 
 
the physical and environment domains and on the overall 
quality of life facet in favor of participants who take 1 
pill per day (Table 9). 
It was carried out a post-hoc LSD (p < 0.001) and it 
was found that the statistically significant differences 
regarding adherence are among the participants taking 1  
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Table 5. Mean differences (Student’s t-test) in treatment adherence and quality of life according to the CD4+ count. 
 CD4+ count 
 <200 200 - 350 351 - 500 >500  
 (n = 65) (n = 63) (n = 65) (n = 102)  
 M SD M SD M SD M SD F p 
Adherence 67.14 12.61 71.21 10.53 71.52 9.56 73.88 9.19 5.59 0.001 
General QoL* 43.85 19.15 51.29 19.89 55.38 21.19 58.33 21.50 6.95 <0.001 
QoL domains           
Physical health  54.89 14.29 57.20 18.51 61.76 17.69 63.48 18.59 3.94 0.009 
Psychological  53.97 18.67 55.95 15.50 59.42 18.41 60.25 18.06 2.06 0.11 
Social relationships  45.00 20.67 49.07 19.98 52.69 23.25 56.94 21.37 4.55 0.004 
Environment  49.90 17.30 51.34 14.82 54.66 17.23 57.84 17.34 3.63 0.01 
*Quality of life. 
 
pill a day and those taking 2, between those who take 1 
and 3, between those who take 1 and 4 and those who 
take 1 and more than 4 tablets per day. For the overall 
quality of life facet it was verified that the statistically 
significant differences are among participants taking 1 
pill a day and those taking 2, among those taking 1 and 3, 
among those taking 1 and 4, among those who take 1 and 
more than 4, among those taking 2 and 4 and among 
those taking more than 4 tablets per day (Table 10). 
4. Discussion 
The aim of this study was to analyze the relationship be- 
tween treatment adherence, quality of life and clinical va- 
riables in HIV/AIDS infection. Some disease and treat- 
ment related variables appear to compromise adherence 
and quality of life levels. It was found statistically signi- 
ficant differences in adherence and quality of life in rela- 
tion to HIV stage and biological markers of HIV infec- 
tion-viral load and on the CD4+ T cell count, which is in 
agreement with other studies [6,9,10]. With respect to 
disease stage, while some studies indicate improved ad- 
herence in symptomatic and AIDS stage patients [11,24, 
25] that does not happen in our study: our results suggest 
that asymptomatic subjects show a higher adherence 
level. One possible explanation for this result is that fear 
of future complications may create an incentive for in- 
creased adherence in asymptomatic patients. 
Considering the biological markers it was found that 
subjects with undetectable viral load and CD4 + T > 500 
cell count have better levels of adherence and better in- 
sight of quality of life. These results are in line with 
those presented in the literature on the benefits of anti- 
retroviral therapy in reducing viral load and restoration 
of immunity [6,9,10,14]. 
With respect to therapeutic regimen, the available evi- 
dence suggests that want both the number of daily in- 
takes [25] and the number of pills per day [26,27] are of 
relevance in increasing the probability of higher adher- 
ence levels. Our results confirm that evidence, indeed we 
find that patients on a single tablet regimen have both 
higher adherence and higher quality of life. These results 
reinforce the importance of the complexity of the treat- 
ment as adherence barrier [28]. Further, they reinforce 
the fact the lower the level of interference of treatment in 
daily life, the higher the average adherence level [6,10, 
29]. 
With regard to side effects, as expected participants 
who reported experiencing side effects associated with 
antiretroviral treatment are found to have a lower adher- 
ence levels and worse quality of life. This result is en- 
tirely consistent with prior studies on the impact side ef- 
fects can have on the adherence and quality of life [12, 
30]. Indeed, side effects (often severe and complex) are 
described in the literature as predictors of poor adherence 
[29]. It is, thus, important to monitor side effects when 
starting or switching therapy [31]. 
5. Conclusions 
Clinical variables and regimen characteristics were found 
to be associated with adherence and QoL. We were able 
to find significant evidence of positive association be- 
tween treatment simplification in adherence and QoL. 
For instance, reducing the number of pills and the num- 
ber of daily doses is found to be associated with higher 
adherence and better QoL. The results also reinforce the 
widely described in the literature barrier to adequate ad- 
herence generated by treatment complexity. These aspects 
should thus be considered when defining interventions to 
improve adherence to antiretroviral therapy.  
The study does have some limitations. Adherence was 
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Table 6. Mean differences (Student’s t-test) in treatment adherence and quality of life according to the CD4+ cell count— 
Post-hoc Tukey. 
 CD4+ cell count CD4+ cell count Mean difference p 
200 - 350 −4.07 0.12 
351 - 500 −4.39 0.08 <200 
>500 −6.74 <0.001 
351 - 500 −0.32 0.99 
200 - 350 
>500 −2.68 0.38 
Adherence 
351 - 500 >500 −2.36 0.48 
200 - 350 −7.74 0.15 
351 - 500 −11.54 0.008 <200 
>500 −14.49 <0.001 
351 - 500 −3.97 0.72 
200 - 350 
>500 -6.75 0.17 
General QoL* 
351 - 500 >500 −2.95 0.80 
QoL domains      
200 - 350 −2.31 0.88 
351 - 500 −6.86 0.16 <200 
>500 −8.56 0.01 
351 - 500 −4.56 0.46 
200 - 350 
>500 −6.28 0.12 
Physical health  
351 - 500 >500 −1.72 0.93 
200 - 350 −1.98 0.92 
351 - 500 −5.45 0.33 <200 
>500 −6.23 0.18 
351 - 500 −3.47 0.69 
200 - 350 
>500 −4.30 0.43 
Psychological 
351 - 500 >500 −0.83 0.99 
200 - 350 −4.07 0.70 
351 - 500 −7.69 0.17 <200 
>500 −11.99 0.003 
351 - 500 −3.17 0.77 
200 - 350 
>500 −7.87 0.10 
Social relationships 
351 - 500 >500 −4.25 0.59 
200 - 350 −1.44 0.96 
351 - 500 −4.76 0.37 <200 
>500 −7.94 0.02 
351 - 500 −3.32 0.67 
200 - 350 
>500 −6.50 0.08 
Environment 
351 - 500 >500 −3.18 0.63 
*Quality of life. 
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Table 7. Mean differences (Student’s t-test) in treatment adherence and quality of life according to the class of drug and ad- 
verse events of antiretroviral medication. 
 Class of drug Adverse events of antiretroviral medication  
 NRTI
* + 
NNRTI** NRTI + PI
***   Yes No  
 (n = 194) (n = 98)   (n = 113) (n = 182)  
 M SD M SD t p M SD M SD t p 
Adherence 72.40 10.44 69.08 10.83 0.35 0.012 66.96 11.23 74.00 9.23 5.57 <0.001
General QoL**** 55.73 19.76 47.32 22.65 3.27 0.001 47.57 22.15 56.46 19.92 3.57 <0.001
QoL Domains:             
Physical health 61.43 18.01 56.74 17.14 2.14 0.12 55.03 16.97 62.87 17.62 3.77 <0.001
Psychological 58.87 17.04 55.40 19.25 1.57 0.12 58.88 17.54 60.81 17.43 3.79 <0.001
Social relationships 51.46 21.43 57.79 22.43 0.12 0.90 47.12 20.77 54.53 21.91 2.88 0.004 
Environment 55.32 16.60 51.15 17.49 1.99 0.04 50.11 15.92 56.42 17.28 3.14 0.002 
*Nucleoside reverse transcriptase inhibitors; **non nucleoside reverse transcriptase inhibitors; ***protease inhibitors; ****quality of life. 
 
Table 8. Mean differences (Student’s t-test) in treatment adherence and quality of life according to the number of doses per 
day. 
 Number of doses per day  
 1 2  
 (n = 158) (n = 134)  
 M SD M SD t p 
Adherence 73.54 9.56 6893 11.18 3.76 <0.001 
General QoL* 55.93 20.14 4963 22.16 2.55 0.001 
QoL domains       
Physical health 61.84 17.25 57.41 18.07 2.14 0.03 
Psychological 60.86 16.28 54.32 19.00 3.13 0.002 
Social relationships 52.06 21.99 51.24 21.66 0.32 0.75 
Environment 56.59 16.01 50.93 17.80 2.86 0.005 
*Quality of life. 
 
Table 9. Mean differences (One-Way ANOVA) in treatment adherence and quality of life according to the number of pills per 
day. 
 Number of pills per day  
 1 2 3 4 >4  
 (n = 26) (n = 53) (n = 90) (n = 37) (n = 89)  
 M SD M SD M SD M SD M SD F p 
Adherence 78.04 5.11 73.11 10.84 71.63 10.57 68.70 9.27 69.01 11.36 4.84 0.001
General QoL* 64.90 13.70 58.25 19.14 53.75 21.97 46.96 18.96 48.31 22.39 4.98 0.001
QoL domains             
Physical health  66.62 16.93 63.14 16.59 60.63 18.42 55.12 16.38 56.98 17.82 2.83 0.03 
Psychological  61.38 14.56 60.61 16.09 58.56 18.07 54.28 17.19 55.66 19.50 1.31 0.27 
Social relationships  53.53 22.51 51.10 19.86 51.67 22.66 50.00 19.64 52.25 22.85 0.13 0.97 
Environment  58.05 14.80 57.96 15.87 54.90 17.75 49.58 15.47 51.40 17.62 2.33 0.05 
*Quality of life. 
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Table 10. Mean differences (One-Way ANOVA) in treatment adherence and quality of life according to the number of pills 
per day—Post-hoc LSD. 
 Pills per day Pills per day Mean difference p 
2 4.93 0.048 
3 6.41 0.006 
4 9.34 0.001 
1 
>4 9.03 <0.001 
3 1.48 0.41 
4 4.41 0.048 2 
>4 4.10 0.02 
4 2.93 0.15 
3 
>4 2.62 0.09 
Adherence 
4 >4 −0.31 0.88 
2 6.65 0.18 
3 11.15 0.02 
4 17.94 0.001 
1 
>4 11.59 <0.001 
3 4.51 0.21 
4 11.23 0.01 2 
>4 9.94 0.006 
4 6.80 0.09 
3 
>4 5.45 0.08 
General QoL* 
4 >4 −1.34 0.74 
QoL domains     
2 3.21 0.45 
3 5.90 0.13 
4 11.51 0.01 
1 
>4 9.64 0.01 
3 2.78 0.36 
4 8.30 0.03 2 
>4 6.43 0.04 
4 5.52 0.12 
3 
>4 3.65 0.17 
Physical health 
4 >4 -1.87 0.59 
2 0.77 0.86 
3 2.81 0.48 
4 7.09 0.12 
1 
>4 5.71 0.15 
3 2.05 0.51 
4 6.33 0.98 2 
>4 4.95 0.11 
4 4.30 0.22 
3 
>4 2.90 0.28 
Psychological 
4 >4 −1.39 0.69 
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Continued 
2 2.43 0.64 
3 1.86 0.70 
4 3.53 0.53 
1 
>4 1.28 0.80 
3 −0.57 0.88 
4 1.10 0.81 2 
>4 −1.15 0.76 
4 1.68 0.70 
3 
>4 −0.58 0.86 
Social relationships 
4 >4 −2.25 0.60 
2 0.09 0.98 
3 3.16 0.40 
4 8.48 0.05 
1 
>4 6.65 0.08 
3 3.06 0.30 
2 
4 8.38 0.02 
 >4 6.56 0.03 
3 4 5.32 0.11 
 >4 3.50 0.17 
Environment 
4 >4 −1.83 0.58 
*Quality of life. 
 
assessed through a self-reporting adherence questionnaire 
and these results then confronted with biological markers 
(patient’s viral load and CD4 count). Despite concerns 
that self-reporting may overestimate adherence, it has been 
demonstrated that self-reported adherence has been con- 
sistently correlated with viral load and clinical outcomes 
in HIV treatment [6,12,16] and has been deemed a robust 
and appropriate indicator of adherence.  
This study is a cross-sectional study, which measured 
adherence and QoL at a single time point. However, ad- 
herence and QoL are dynamic processes that may change 
over time. Longitudinal studies with a wider range of re- 
spondents and the use of a combination of adherence as- 
sessment tools are necessary to understand adherence and 
QoL over time and to explore the factors that influence 
adherence to antiretroviral therapy in the longer term, 
which could most likely reduce the risk of overestimation 
[32]. 
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